Live Breaking News & Updates on நாஸ்டாக் மூலதனம்|Page 27
Stay updated with breaking news from நாஸ்டாக் மூலதனம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Color Star Technology Co., Ltd. (NASDAQ: CSCW) (hereinafter referred to as "Color Star" or the "Company"), announced today that it has received a letter from the NASDAQ Listing Qualifications Staff notifying the Company that it has regained compliance with NASDAQ's minimum bid price requirements for continued listing on the Nasdaq Capital Market. Color Star Technology Co., Ltd. (NASDAQ: CSCW) (hereinafter referred to as "Color Star" or the "Company"), announced today that it has received a letter from the NASDAQ Listing Qualifications Staff notifying the Company that it has regained compliance with NASDAQ's minimum bid price requirements for continued listing on the Nasdaq Capital Market. The letter noted that as. ....
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Medigus: Polyrizon Commenced a Pre-Clinical Study Testing Several Formulations of its Bio-Gel . Medigus LtdApril 12, 2021 GMT OMER, Israel, April 12, 2021 (GLOBE NEWSWIRE) Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions and innovative internet technologies, today announced that Polyrizon Ltd. (which Medigus owns 33.24% of its share capital), a private company engaged in developing highly differentiated biological gels for the purpose of protecting patients against biological threats and external pathogens, commenced a pre-clinical trial to examine its bio-gel efficacy to protect against coronavirus infection. ....
"Buzz on the Street" Show: Color Star Technology Co., Ltd. (NASDAQ: CSCW) Regains NASDAQ Compliance | "Buzz on the Street" Show: Color Star Technology Co., Ltd. (NASDAQ: CSCW) Regains NASDAQ ComplianceFinancial Buzz financialbuzz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialbuzz.com Daily Mail and Mail on Sunday newspapers.
Photo by istock.com April 7, 2021 Muscle Maker Inc. has made a deal for a private placement with a single investor to buy up to 1.25 million shares of stock and approximately 2.87 million pre-funded warrants, each capable of being used as one share, according to a news release. Each share and warrants are being sold as a combined offering for $2.43, according to a press release. Each share and warrant are being sold jointly for a combined offering price of $2.43, while each pre-funded warrant and its accompanying warrant are being offered at a combined cost of $2.42, the release said. We are very pleased that we are able to take the first steps in moving forward with the private placement, CEO Michael Roper said in the release, This funding, when closed, will allow Muscle Maker to continue to execute our non-traditional location growth strategy as well as provide the ability to identify and acquire additional concepts that complement our business model like the ....
Cardiol Therapeutics Inc.: Cardiol Therapeutics Announces Filing of 2020 Year-End Financial Statements and MD&A Cardiol Therapeutics Inc. ( a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, today filed its audited Financial Statements and Management s Discussion and Analysis for the year ended December 31, 2020. Both are available under the Company s profile on SEDAR at www.sedar.com and on the Company s website at www.cardiolrx.com. David Elsley, President and Chief Executive Officer of Cardiol, commented: 2020 was a very exciting year for Cardiol Therapeutics. We made extraordinary progress in our research and clinical development programs, while significantly strengthening our financial position. We are particularly excited about the progress made across our research and development programs supporting the development of CardiolRx, our pharmaceutically produced extra- ....